UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 15, 2025

ABSCI CORPORATION
(Exact name of registrant as specified in its charter)

Delaware	**001-40646**	**85-3383487**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

18105 SE Mill Plain Blvd
Vancouver, WA 98683
(Address of principal executive offices, including zip code)

(360) 949-1041
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	ABSI	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On January 15, 2025, Absci Corporation (the "Company") announced that it will present a business update at the 43rd Annual J.P. Morgan Healthcare Conference. A copy of the slides from the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The presentation is available in the "Events and Presentations" section of the Company's investor relations website at investors.absci.com.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits

99.1 Slides from the Company's presentation filed on January 15, 2025.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Absci Corporation

Date: January 15, 2025

By: /s/ Shelby Walker

Shelby Walker

Chief Legal Officer

absci

```
from absci import de_novo_model
model = de_novo_model.load_latest()
antigen = model.load_pdb("7olz.pdb",
chain="A")
antibodies = model.predict(antigen, N=300000)
```

```
from absci_library import codon_optimizer
library
= codon_optimizer.reverse_translate(library)
library.to_csv("covid-antibody-designs.csv")
library.to_wet_lab(assay="ACE")
```

```
from absci import lead_opt_model
lead_optimizer = lead_opt_model.load_latest()
library.naturalness =
lead_optimizer.naturalness(library)
lead_optimizer.optimize(library).to_wet_lab(as
say="SPR")
```

GENERATIVE AI DRUG CREATION

2025 J.P. MORGAN HEALTHCARE CONFERENCE

```
from absci import genetic_algorithm; parameters=["maximize|binding_affinity:pH=7.5", "minimize|binding_affinity:pH=6.0",
"maximize|human_naturalness"]; library = genetic_algorithm.multiparametric_optimization(library, parameters, evolutions=100);
library.to_wet_lab(assays=["ACE", "SPR", "Bioassays"])
```

Disclaimers

Forward-Looking Statements
Certain statements in this presentation that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words "will," "may," "anticipates," "plans," "believes," "forecast," "estimates," "expects," "predicts," "advancing," "aim," and "intends," or similar expressions. We intend these forward-looking statements, including statements regarding our strategy, our expectations regarding the clinical, therapeutic and market potential of product candidates discovered and developed through our platform; the potential advantages of our technology and the assets in our internal pipeline; our ability to achieve catalysts in our preclinical and clinical development programs, such as the initiation of IND-enabling studies and Phase 1 clinical development and the receipt of clinical data; the anticipated timing of such events; the expected evolution of our portfolio over time; guidance regarding cash, cash equivalents and our projected cash runway, our future operations, internal research and technological development activities, estimated speed and cost advantages of leveraging our AI drug creation platform; our expectations regarding the status and progress of our existing partnerships and our plans for potential new partnerships; our expected operational efficiencies, research and technology development collaboration efforts, growth plans, prospects, plans and objectives of management, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to the development of our technology as well as the assets in our internal pipeline, our ability to secure milestone payments and royalties, and our ability to effectively conduct research, drug discovery and development activities with respect to our internal programs and to collaborate with our partners or potential partners with respect to their research, drug discovery and development activities; along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

Market and Statistical Information
This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other industry data. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified the data generated by independent parties and cannot guarantee their accuracy or completeness.

Trademark usage
This presentation/document/webpage contains references to our trademarks and service marks and to those belonging to third parties. Absci®, a ®, SoluPro®, Bionic SoluPro® and SoluPure® are Absci registered trademarks with the U.S. Patent and Trademark Office. We also use various other trademarks, service marks and trade names in our business, including the Absci AI logo mark (al.), the Unlimit with us mark (Unlimit With Us®), Denovium, Integrated Drug Creation, HiPrBind, and IgDesign. All other trademarks, service marks or trade names referred to in this presentation/document/webpage are the property of their respective owners. Solely for convenience, the trademarks and trade names in this presentation/document/webpage may be referred to with or without the trademark symbols, but references which omit the symbols should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

PLATFORM

- Launched latest *de novo* antibody design models unlocking previously undruggable targets ie: HIV "Caldera"
- Successful execution in partnerships including with: AstraZeneca, Almirall, and Caltech

PARTNERSHIPS

- Strategic Collaboration with AMD committing $20M equity investment in Absci
- Achieved 2024 partnership guidance with 4 new partners announced: MSKCC, Twist Bioscience, Invetx & Owkin

PIPELINE

- ABS-101: "Best-in-class" potential anti-TL1A antibody entering clinic 1H 2025
- ABS-201: nomination of drug candidate for androgenic alopecia addressing significant clinical and commercial opportunity
- ABS-301 & ABS-501: lead and candidate ID on novel and differentiated programs designed using AI

Ingredients for Success



Absci's leadership in AI *de novo* antibody design

Since 2020 Absci has been amassing high-quality data at scale for AI model training and validation



Leadership in AI *de novo* design of antibody-based therapeutics

DE NOVO ANTIBODY DESIGN



- *de novo* antibody design model creates epitope-specific binders given a target structure
- Designed in framework of choice or multiple frameworks

AI LEAD OPTIMIZATION



- Co-optimization enables improvement of antibody attributes while maintaining developability
- Precise engineering of molecule pharmacology

Leading AI models to create novel & differentiated therapeutics



ADDRESS COMPLEX AND PREVIOUSLY "HARD TO DRUG" TARGETS

- Bind Specific extracellular domains
- Target Specific conformations
- Address difficult target classes e.g. GPCRs

INTRODUCE PRECISE CONTROL OVER ANTIBODY DESIGN

- "Smart" biologics
- Enhanced Potency & MOA
- Engineer selectivity, minimizing off target toxicity
- Agonism vs. Antagonism

Platform Case Studies

DE NOVO ANTIBODY DESIGN

DE NOVO ANTIBODY DESIGN PROGRAM IN COLLABORATION WITH CALTECH FUNDED BY THE GATES FOUNDATION

VIEW THE FULL CASE STUDY

Caltech BILL & MELINDA GATES foundation



- **Goal:** create universally neutralizing HIV antibody by binding conserved epitope within "caldera" region of HIV gp120
- Absci's *de novo* design platform can successfully address difficult to drug target epitopes

AI LEAD OPTIMIZATION

AI LEAD OPTIMIZATION FOR PH SENSITIVITY WHICH MAY REDUCE TOXICITY AND/OR IMPROVE EFFICACY OF THERAPEUTIC mAbs

VIEW THE FULL CASE STUDY



Model searches a massive space of ~10^{19}, identifying functional and developable antibodies in one step.

- **Goal:** Co-optimize antibodies for pH sensitive binding to increase efficacy and reduce
- Absci's lead optimization platform enables molecules with differentiated pharmacology

Since publishing the first work in AI *de novo* antibody design, Absci has continued to rapidly progress and lead the field



de novo Model v1
Absci was the first to design and validate novel antibodies using zero-shot generative AI in BioRxiv preprint

de novo Model v2
Demonstrated *de novo* design model's broad applicability to multiple therapeutic antigens in Neurips publication

de novo Model v3
Successfully designed high affinity binders to an epitope without known binder in Large Pharma partnership

de novo Model v4 and continued development
Successfully *de novo* designed against previously "undruggable" target in HIV "Caldera" program in collaboration with Caltech

absci x AMD

Strategic Collaboration to Accelerate the Future of AI Drug Discovery


Sean McClain
Founder and CEO, Absci
Mark Papermaster
CTO and EVP, AMD

Compute At Scale

Why We Chose AMD: Key Advantages of AMD MI300X Chips

Unmatched Training Resolution

- **Why it matters:** Model large protein complexes without cropping, preserving biological context for superior predictions and model accuracy (validated using Boltz-1)
- **How:** Powered by AMD's industry-leading high-memory capacity.

Accelerated Throughput

- **Why it matters:** Significantly scales in silico antibody design and evaluation, reducing R&D timelines and costs.
- **Proof points:**
  - Ability to design library of **12,000+ *de novo* antibodies** in under 1 week using Absci's IgDesign model
  - Parallelized inference on **1,400 sequences at once** for rapid antibody optimization.
- **How:** Batch processing capabilities powered by AMD's high-memory capacity deliver unmatched speed and efficiency.

Example of complex ion channel which typically needs to be cropped, or apply low-memory architectures to resolve without MI300X GPUs

PDB:8RRV = Ryanodine Receptor isoform 1 (RyR1) in complex with FKBP and Nb9657



PDB:8RRV structure prediction time: 15 minutes

[1]Wohlwend et al. 2024, *bioRxiv*
[2]Shanehsazzadeh et al. 2024, *bioRxiv*
[3]https://github.com/AbSciBio/igdesign

Absci Partnership Ecosystem



OUR PEOPLE

"Multilingual" team with expertise in AI and drug creation

LEADERSHIP TEAM

Sean McClain
Founder, CEO & Director

Andreas Busch, PHD
Chief Innovation Officer

Zach Jonasson, PHD
Chief Financial Officer & Chief Business Officer

Amaro Taylor-Weiner, PHD
SVP, Chief AI Officer

Shelby Walker, JD
Chief Legal Officer

Karin Wierinck
Chief People Officer

Christian Stegmann, PHD
SVP, Drug Creation

Christine Lemke, DVM
SVP, Portfolio & Growth Strategy

Penelope
Chief Morale Officer

BOARD OF DIRECTORS

Frans Van Houten
Chairman of the Board
Former CEO, Royal Phillips

Sean McClain
Founder, CEO & Board Director

Sir Mene Pangalos, PHD
Former EVP R&D AstraZeneca

Karen Mcginnis, CPA
Former Chief Accounting Officer, Illumina

Amrit Nagpal
Managing Director, Redmile Group

Dan Rabinovitsj
VP Hardware Engineering, Meta

Joseph Sirosh, PHD
Former CTO, Compass VP, Amazon & Microsoft

SCIENTIFIC ADVISORY BOARD

Sir Mene Pangalos, PHD
Co-Chair SAB
Former EVP R&D AstraZeneca

Andreas Busch, PHD
Co-Chair SAB
Chief Innovation Officer

Ian McInnes, PHD
Vice Principal and Head of College University of Glasgow

Luis Diaz, MD
Head, Division of Solid Tumor Oncology Memorial Sloan Kettering Cancer Center

John Wherry, PHD
Director, Institute for Immunology & Immune Health, University of Pennsylvania

Victor Greiff, PHD
Associate Professor University of Oslo

Hubert Truebel, MD, PHD, MBA
Chief Medical Officer AiCuris

EXPERTISE & BACKGROUND FROM

OpenAI · Google · NVIDIA · Harvard University · Stanford University · MIT · Tesla · Takeda · X · AstraZeneca · Broad Institute · Bayer · Pfizer · Bristol Myers Squibb · Novo Nordisk · Philips · Shire · amazon · Meta · Microsoft · PathAI

AI PIPELINE

Advancing and expanding our pipeline of novel & differentiated assets designed using AI



KEY HIGHLIGHTS

ABS-101
FiH in 1H25 and Ph1 Interim data readout 2H25. New preclinical data support potentially superior immunogenicity profile.

ABS-201
Category defining PRLR antibody for androgenic alopecia. IND-enabling activities initiated, with potential to be first in U.S market.

ABS-301
Potential first-in-class asset with target validation and initial preclinical efficacy readouts in 1H25.

ABS-501
Candidate ID phase for novel HER2 program designed using *de novo* AI

ABS-101 TL1A

Latest NHP data confirm compelling profile and target engagement



Non-Human Primates(NHP) single dose PK/PD study highlights:

- Confirmatory target engagement
- Dose dependency of target engagement including ceiling effect
- Significant improved target engagement vs. competitor molecules at comparative dosing regimen

Data Advantage
Leading AI Models
Compute At Scale
"Multilingual" Expertise

ABS-201 has the potential to unlock a wholly new category of therapy in hair "re-growth"

CLINICAL AND COMMERCIAL UNMET NEED

- Significant unmet clinical need for androgenic alopecia
- Large market: 80-90M patients in U.S., which is a highly motivated patient population

SCIENTIFIC RATIONALE

- Highly validated target (efficacy & safety) for treatment of androgenic alopecia
- Supportive pharmacological profile of ABS-201

DEVELOPMENT PATH

- Straightforward clinical development path with option for early Proof of Concept
- Low competition, potentially first to U.S. market

ABS-201

Significant underserved patient population looking for therapeutic innovation

80 - 90 MILLION AMERICANS LIVE WITH ANDROGENIC ALOPECIA



MALE ANDROGENIC ALPOPECIA

- ~50M men in the U.S.
- Only 2 FDA approved therapies



FEMALE ANDROGENIC ALOPECIA

- ~30M women in U.S.
- Only 1 FDA approved therapy for women

- **Growing patient population with limited therapeutic options and side-effect concerns**
- **Last FDA approved therapy for androgenic alopecia was in the 1990s**
- **Patients and clinicians need better treatment options for "hair re-growth"**
  - Hair re-growth, not just slowing of hair loss
  - Safe and minimal side effects
  - Durable effect
  - Convenient administration frequency
  - FDA approved

ABS-201

Prolactin Receptor inhibition is an innovative alternative to current treatment options

Proposed impact of ABS-201 on Hair Cycle Stages



ABS-201 has the potential to:

- Shift the balance in hair cycle stage towards anagen phase[1,2] with:
  - active and new hair growth
  - prevention of telogen effluvium
- Promote a long-lasting effect after treatment cessation
- Prevent prolactin mediated telogen effluvium[1,2]
- Restore hair pigmentation[2]

[1] doi: 10.1016/S0002-9440(10)64295-2
[2] doi: 10.2353/ajpath.2006.050468

Translational Model validates PRLR Target

TOP HEAD VIEW OF STUMPTAILED MACAQUE'S SHOWING PHENOTYPIC CHANGE OVER TIME



40mg/kg s.c. Q2W for 28 weeks

Disclosure from competitor

Treatment with an anti-PRLR mAb promotes and sustains long-term hair growth in NHP

- Hair density & thickness improved with short treatment duration in primate model of androgenic alopecia
- Hair growth remains several years post cessation
- Hair regrowth observed for both male and female animals

ABS-201

ABS-201 shows superior efficacy vs 5% topical minoxidil in 21d hair regrowth model





Administration: mAbs i.p. biweekly; Minoxidil topical daily

ABS-201 vs minoxidil/untreated/isotype **p<0.05; ***p<0.0001 - 2way ANOVA

Data Advantage

Leading AI Models

Compute At Scale

"Multilingual" Expertise

ABS-201 represents a significant untapped new market opportunity

UNLOCKS WHOLLY NEW CATEGORY OF THERAPY

- Lack of innovation and effective treatments in the hair loss space
- Hair is long considered the last frontier of medical aesthetics market

STRONG WILLINGNESS TO SELF-PAY ACROSS DEMOGRAPHICS

- Consumers across income levels invest in aesthetic treatments, driving steady demand.

$14B+ MARKET WITH SIGNIFICANT UPSIDE POTENTIAL

- Potential 2-3X larger depending on clinical profile and additional indications such as hair re-pigmentation

Source: BCG

CATALYSTS

Leading AI platform driving numerous near-term value inflection points